1 mg
8 mini trochesOne a day at most, eight a month
Sublingual or buccal mini troche. About $13.63 a dose at eight doses a month.
$54.50first month, then $109
Start at 1 mgPT-141 Troches8 troches · 30-day package
From $54.50 first monthGet started
About $13.63 a dose
PT-141 · mini troche
Pick your strength. Then stop scheduling desire.
PT-141 mini troches, 1 mg or 2 mg. Eight doses in every package.
A small troche dissolves under your tongue or in your cheek. The peptide inside goes at the melanocortin pathway, the one that drives wanting, rather than the blood-flow pathway the older category treats.
- 1 mg or 2 mg, so a provider can start you low
- Eight doses in a 30-day package
- Take one when you want it, one a day at most
- Nothing to swallow, nothing to inject
$54.50 your first month, then $109 monthly.
Sublingual or buccal mini trocheNeedle-free route
One a day at most, eight a monthTaken as needed
U.S. pharmacyCompounded to order
Free deliveryPlain packaging
Two strengths
Start at 1 mg. Move to 2 mg if you want more.
Both packages hold eight mini troches. The strength decision belongs to you and the provider who reads your visit.
2 mg
8 mini trochesOne a day at most, eight a month
Sublingual or buccal mini troche. About $14.88 a dose at eight doses a month.
$59.50first month, then $119
Start at 2 mgBoth strengths include the online visit, the licensed provider review, the medication from a U.S. compounding pharmacy, and free delivery in plain packaging.
Why the troche
The cheapest way onto the desire pathway.
At about a quarter of a nasal dose in price, the troche is the easiest first step onto PT-141. It also gives a provider a real dial to turn.
- 01A strength you can move
1 mg and 2 mg are both stocked. If 1 mg is not enough, the change is a message to your care team, not a new visit.
- 02No clock to watch
You take a troche before you want the evening to go somewhere. There is no scheduled window to hit.
- 03Discreet by design
A small jar of mini troches. It looks like nothing, it travels like nothing, and it arrives in plain packaging.
How it reaches you
Under the tongue or in the cheek.
Sublingual means under the tongue. Buccal means between gum and cheek. Both are mucosal placements, which is why a troche is not the same thing as swallowing a peptide.
The molecule
Bremelanotide, the same compound in every PT-141 format
A synthetic analogue of alpha-melanocyte-stimulating hormone that acts as an agonist at the MC3R and MC4R melanocortin receptors.
Diamond LE et al. J Sex Med. 2006;3(4):628-638.The pathway
Melanocortin receptors sit on the desire circuitry
Melanocortins take part in a range of physiological responses, sexual behaviour among them. PDE5 medicines act further downstream on blood flow.
Diamond LE et al. J Sex Med. 2006;3(4):628-638.The boundary
No trial has tested a PT-141 troche
Published human research on bremelanotide used the subcutaneous injection and, in early work, an intranasal formulation. There is no route-matched trial for a troche, and we will not pretend there is.
Rebody research note, 2026.Intimacy results
The point is feeling spontaneous again.
Verified Rebody customers on the pt-141 troches.
01
I was uncomfortable bringing this up, but my Rebody doctor made the conversation feel normal. The PT-141 troches have helped with desire, and things feel more spontaneous with my husband again. The package was discreet and arrived when expected.
02
PT-141 works for me. More desire, easy to take, and Rebody customer service has been quick the couple times I've had questions.
03
I almost canceled the appointment because this was not an easy subject for me to talk about. My Rebody doctor was kind, professional and made me comfortable from the first conversation. The PT-141 troches have made a real difference in my desire and in my relationship with my husband. Everything arrived discreetly, and customer service has been wonderful.
What your label decides
The jar is fixed. The directions are yours.
The strength, the count, and the monthly limit are set by the product. It ships cold and lives in the fridge. Placement and timing are written on the prescription label your provider signs.
Where it is made
Made by Kaduceus, to your prescription.
Your troches are compounded by Kaduceus, a licensed 503A compounding pharmacy in the United States. A 503A pharmacy works against a prescription written for one patient, which is why your name and your strength are on the jar.
- Licensed 503A compounding pharmacy
- Compounded in the United States
- Made to your prescription, not to a shelf
- One active, at the strength printed on your label
Getting it
Written down once, then handled.
No appointment, no pharmacy counter, and no repeating yourself to a receptionist.
- 01
Answer the private questions
Desire, medicines, blood pressure, heart history, and what you have already tried. No appointment and no waiting room.
- 02
A licensed provider reads it
A U.S.-licensed clinician reviews your history and decides the route and the strength that fit you.
- 03
The pharmacy makes it
A licensed U.S. compounding pharmacy prepares your PT-141 and ships it in plain packaging.
- 04
Keep the thread open
Message your care team about timing, strength, side effects, or refills. Pause or cancel whenever you want.
The other route
PT-141 Nasal Spray is here too.
You want the route with early human intranasal research behind it. 5 mL bottle · 30-day package, from $99.50 for the first month.
See the nasal spray
PT-141 Troches questions
Know the jar before you start.
Strengths, directions, research, and how a route change works.
How do I take a PT-141 troche?
You let it dissolve in your mouth before anticipated sexual activity, either under the tongue or between gum and cheek. Take no more than one troche in 24 hours and no more than eight in a month. Keep the jar refrigerated between doses. Your prescription label carries the placement and timing directions your provider writes.
Should I start at 1 mg or 2 mg?
That is the provider's call after reading your visit. Many people start at 1 mg. If it is not enough, you message your care team and a provider reviews the change.
What research exists for the troche route?
Published human research on bremelanotide covers the subcutaneous injection and an early intranasal formulation. There is no human outcome or pharmacokinetic trial for a PT-141 troche. What is established is the compound and its action at melanocortin receptors.
Is this the same as Vyleesi?
No. Vyleesi is the FDA-approved 1.75 mg bremelanotide autoinjector for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The Rebody troche is a compounded prescription medication. It is a different product and it does not carry that approval or that indication.
What is in a package?
Eight mini troches at your prescribed strength, prepared by a licensed U.S. compounding pharmacy, shipped in plain packaging with your directions.
Can I switch to the nasal spray?
Yes. Message your care team and a provider reviews the route change. Your plan and refill timing update from there.
Important safety information
What a provider needs to know before prescribing.
Bremelanotide's approved label is contraindicated in uncontrolled high blood pressure and in known cardiovascular disease. Tell your provider your blood pressure, your heart history, every medicine and supplement you take, whether you take naltrexone, and whether you are pregnant or breastfeeding.
Nausea, flushing, and headache were the reactions most often reported in bremelanotide trials. The approved label also covers a temporary rise in blood pressure, a fall in heart rate, and darkening of skin in patches. Get urgent care for hives, swelling, trouble breathing, chest tightness, or fainting.
The FDA-approved bremelanotide product is Vyleesi, a 1.75 mg subcutaneous autoinjector for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Rebody's troche and nasal spray are compounded prescription medications. They are a different product and they do not carry that approval or that indication.
Compounded medications are not FDA-approved or evaluated by the FDA for safety, efficacy, or quality. Prescription treatment requires a provider decision and is not available in every state.PT-141 Troches
One troche, and the evening is not a negotiation.
$54.50 for your first month, then $109. The visit, the provider review, and delivery are in the price.